HRMY vs JAZZ vs SUPN vs AVPT

For growth investors, AvePoint, Inc.

(AVPT) is the stronger pick with 26. 9% revenue growth year-over-year, versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). Harmony Biosciences Holdings, Inc. (HRMY) offers the better valuation at 11. 6x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate Harmony Biosciences Holdings, Inc. (HRMY) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Harmony Biosciences Holdings, Inc.

(HRMY) is the cheapest at 11. 6x versus AvePoint, Inc. at 68. 8x. On forward P/E, Harmony Biosciences Holdings, Inc. is actually cheaper at 9. 0x.

Over the past 5 years, Supernus Pharmaceuticals, Inc.

(SUPN) delivered a total return of +78. 0%, compared to +1. 7% for AvePoint, Inc. (AVPT). Over 10 years, the gap is even starker: SUPN returned +228. 4% versus HRMY's -15. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Jazz Pharmaceuticals plc (JAZZ) is the lower-risk stock at 0.

65β versus AvePoint, Inc. 's 1. 06β — meaning AVPT is approximately 64% more volatile than JAZZ relative to the S&P 500. On balance sheet safety, AvePoint, Inc. (AVPT) carries a lower debt/equity ratio of 2% versus 126% for Jazz Pharmaceuticals plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AvePoint, Inc.

(AVPT) is pulling ahead at 26. 9% versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). On earnings-per-share growth, the picture is similar: AvePoint, Inc. grew EPS 193. 8% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Over a 3-year CAGR, HRMY leads at 25. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Harmony Biosciences Holdings, Inc.

(HRMY) is the more profitable company, earning 18. 3% net margin versus -8. 3% for Jazz Pharmaceuticals plc — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HRMY leads at 24. 0% versus -5. 1% for SUPN. At the gross margin level — before operating expenses — SUPN leads at 89. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Harmony Biosciences Holdings, Inc.

(HRMY) trades at 9. 0x forward P/E versus 27. 7x for AvePoint, Inc. — 18. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVPT: 69. 6% to $17. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Jazz Pharmaceuticals plc (JAZZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65)). Both have compounded well over 10 years (JAZZ: +53. 7%, AVPT: +5. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HRMY (Healthcare) and JAZZ (Healthcare) and SUPN (Healthcare) and AVPT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HRMY is a small-cap high-growth stock; JAZZ is a mid-cap quality compounder stock; SUPN is a small-cap quality compounder stock; AVPT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.